Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ASCO Round-Up: Chronix Delta Dots, HTG EdgeSeq, and Guardant360 Liquid Biopsy

This article was originally published in Clinica

Executive Summary

The annual American Society of Clinical Oncology (ASCO) conference June 3-7 in Chicago was dominated by drug trials, but also included many presentations on new diagnostic technologies.

You may also be interested in...



Liquid Biopsy In Oncology: An Increasingly Crowded Landscape

Liquid biopsies – carrying out diagnostic tests on liquid samples such as blood or urine rather than on tissue biopsy material – look set to revolutionize the management of cancer patients. This area has recently captured the interest of a growing number of diagnostic players, both big and small, and spawned the development of different approaches to liquid biopsy. This article marks out who's who in this increasingly busy landscape and the key technologies that are showing promise, and looks at the obstacles that companies are facing.

CMR Signs Deal With J&J To Bring Robots To Europe And South America

CMR Surgical will collaborate with Johnson & Johnson/Ethicon to expand access to its Versius robotic surgery system.

Cordis Looks To Regain Previous Innovation Edge With Drug-Eluting Balloons

Medtech Insight followed-up with Cordis CEO Shar Matin to talk about the company’s path forward as an innovative intervention company following the acquisition of MedAlliance.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT103498

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel